Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials.

Brendon L NeuenMegumi OshimaRajiv Agarwal Clare Arnott David Z I CherneyRobert EdwardsAnna Maria LangkildeKenneth W MahaffeyDarren K McGuire Bruce C Neal Vlado PerkovicAnnpey PongMarc S Sabatine Itamar Raz Tadashi ToyamaChristoph WannerDavid Collins Wheeler Stephen D WiviottBernard ZinmanHiddo J Lambers Heerspink

Published in: Circulation (2022)

SGLT2 inhibitors reduce the risk of serious hyperkalemia in people with type 2 diabetes at high cardiovascular risk or with chronic kidney disease without increasing the risk of hypokalemia.

Keyphrases

chronic kidney disease
randomized controlled trial
end stage renal disease
electronic health record
big data
systematic review
clinical trial
meta analyses